Menu
Search
|

Menu

Close
X

Lupin Ltd LUPN.NS (National Stock Exchange of India)

747.35 INR
-8.80 (-1.16%)
As of Jul 19
Previous Close 756.15
Open 758.00
Volume 796,473
3m Avg Volume 1,866,971
Today’s High 763.00
Today’s Low 742.15
52 Week High 986.10
52 Week Low 697.20
Shares Outstanding (mil) 452.59
Market Capitalization (mil) 338,243.69
Forward P/E 55.91
Dividend (Yield %) 5.00 ( 0.67 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.92 Mean rating from 39 analysts

KEY STATS

Revenue (mm, INR)
FY19
167,182
FY18
158,308
FY17
174,943
FY16
142,555
EPS (INR)
FY19
13.345
FY18
5.497
FY17
56.467
FY16
49.898
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
55.91
34.52
Price to Sales (TTM)
vs sector
2.02
7.97
Price to Book (MRQ)
vs sector
2.46
4.45
Price to Cash Flow (TTM)
vs sector
19.89
24.33
Total Debt to Equity (MRQ)
vs sector
59.83
17.60
LT Debt to Equity (MRQ)
vs sector
48.33
12.58
Return on Investment (TTM)
vs sector
2.87
12.69
Return on Equity (TTM)
vs sector
4.44
17.17

EXECUTIVE LEADERSHIP

Manju Gupta
Chairman of the Board, Since 2017
Salary: Rs4,570,000.00
Bonus: --
Vinita Gupta
Chief Executive Officer, Executive Director, Since 2013
Salary: Rs123,880,000.00
Bonus: --
Kamal Sharma
Non-Executive Vice Chairman of the Board, Since 2018
Salary: Rs107,290,000.00
Bonus: --
Sunil Makharia
Interim Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Debabrata Chakravorty
President – Global Sourcing & Contract Manufacturing, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

B/4 Laxmi Towers
, Bandra Kurla Complex, Bandra (
MUMBAI     400051

Phone: +9122.66402222

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

SPONSORED STORIES